Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Cash from Operations (2020 - 2025)

Historic Cash from Operations for Ensysce Biosciences (ENSC) over the last 6 years, with Q3 2025 value amounting to -$1.9 million.

  • Ensysce Biosciences' Cash from Operations fell 8290.21% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.0 million, marking a year-over-year increase of 1751.58%. This contributed to the annual value of -$7.5 million for FY2024, which is 3040.16% up from last year.
  • Ensysce Biosciences' Cash from Operations amounted to -$1.9 million in Q3 2025, which was down 8290.21% from -$2.7 million recorded in Q2 2025.
  • Over the past 5 years, Ensysce Biosciences' Cash from Operations peaked at -$132312.0 during Q2 2021, and registered a low of -$6.7 million during Q3 2022.
  • For the 5-year period, Ensysce Biosciences' Cash from Operations averaged around -$2.7 million, with its median value being -$2.7 million (2025).
  • As far as peak fluctuations go, Ensysce Biosciences' Cash from Operations tumbled by 325607.81% in 2022, and later skyrocketed by 6630.11% in 2023.
  • Over the past 5 years, Ensysce Biosciences' Cash from Operations (Quarter) stood at -$3.8 million in 2021, then increased by 12.53% to -$3.3 million in 2022, then soared by 45.33% to -$1.8 million in 2023, then skyrocketed by 57.59% to -$764090.0 in 2024, then plummeted by 144.24% to -$1.9 million in 2025.
  • Its Cash from Operations was -$1.9 million in Q3 2025, compared to -$2.7 million in Q2 2025 and -$1.7 million in Q1 2025.